Cao, Yanling 曹彥凌
Main board
| Organisation | Position | From | Until | Total Return |
CAGR total return |
CAGR relative return |
||
|---|---|---|---|---|---|---|---|---|
| 1 | * | Antengene Corporation Limited | NEDNon-Executive Director | 2019-02-04 | 2021-12-16 | -43.11% | -40.95% | -35.98% |
| 2 | Boyu Capital Advisory Co. Limited | MDManaging Director | 2011-03 | |||||
| 3 | * | CStone Pharmaceuticals | NEDNon-Executive Director | 2019-05-15 | 2023-01-18 | -64.14% | -24.32% | -21.48% |
| 4 | Gan & Lee Pharmaceuticals Co., Ltd. | DirDirector | 2015-09 | |||||
| 5 | * | Hygeia Healthcare Holdings Co., Limited | NEDNon-Executive Director | 2019-06-03 | 2021-03-30 | 112.31% | 172.81% | 115.13% |
| 6 | * | JW (Cayman) Therapeutics Co. Ltd | INEDIndependent Non-Executive Director | 2020-05-22 | 2021-12-03 | -46.91% | -44.32% | -43.32% |
| 7 | * | Ocumension Therapeutics | NEDNon-Executive Director | 2019-06-18 | -80.86% | -25.67% | -28.65% | |
| 8 | Viela Bio, Inc. | NEDNon-Executive Director | 2018-02 | |||||
| 9 | * | WuXi Biologics (Cayman) Inc. | NEDNon-Executive Director | 2016-05-11 | 298.44% | 17.33% | 12.91% | |
| Average | 9.15% | -0.23% |
SFC roles
| Organisation | Position | From | Until | ||
|---|---|---|---|---|---|
| 1 | GOLDMAN SACHS (ASIA) L.L.C. | RepRepresentative | 2006-11-01 | 2007-11-17 |
Some data are hidden to fit your display. Rotate?
Total returns are measured from the latest of the start date, the appointment date and 3-Jan-1994 until the earliest of the end date, the resignation/removal date and the last trading date. CAGR is the annualised return and is not shown for periods under 180 days. Relative returns are to the Tracker Fund of HK (2800), starting from the latest of 12-Nov-1999, the appointment date and the chosen start date.
* = is or was HK primary-listed
Webb-site Database - Powered By Linux Group